Eloxx Pharmaceuticals, Inc.

Equities

ELOX

US29014R2022

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 12:05:36 29/05/2024 am IST			5-day change	1st Jan Change
0.8264 ^USD	-2.78%		-2.78%	-31.13%

11/04	North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	DJ
13/03	Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases	CI

Pedro Huertas Intention to Resign as Chief Medical Officer of Eloxx Pharmaceuticals, Inc

August 04, 2018 at 01:47 am IST

Eloxx Pharmaceuticals, Inc. advised by Pedro Huertas of his intention to resign as the company’s Chief Medical Officer. The duties of the Chief Medical Officer will be overseen by the company’s Chief Operating Officer on an interim basis.

Latest news about Eloxx Pharmaceuticals, Inc.

North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	11/04	DJ
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases	13/03	CI
Almirall Signs License Deal with Eloxx Pharmaceuticals for Skin Diseases Treatment	13/03	MT
Eloxx Pharmaceuticals, Inc. Enters into the Fifth Amendment to the Loan and Security Agreement	10/01	CI
Eloxx Pharmaceuticals, Inc. Announces Resignation of Tomer Kariv from the Board	29/12	CI
Eloxx Pharmaceuticals, Inc. and Zikani Therapeutics, Inc. Enter into the Fourth Amendment to the Loan and Security Agreement	16/12	CI
Eloxx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Oppenheimer Adjusts Eloxx Pharmaceuticals Price Target to $30 From $60, Maintains Outperform Rating	02/11	MT
Eloxx Pharmaceuticals, Inc.(NasdaqCM:ELOX) dropped from S&P TMI Index	18/23/18	CI
Eloxx Pharmaceuticals, Inc.(OTCPK:ELOX) dropped from NASDAQ Composite Index	13/23/13	CI
Eloxx Pharmaceuticals, Inc. Announces Resignation of Vijay Modur as Head of Research and Development	16/23/16	CI
Oppenheimer Raises Eloxx Pharmaceuticals Price Target to $60 From $55, Maintains Outperform Rating	14/23/14	MT
Eloxx Pharmaceuticals, Inc. Provides Updates on ELX-02 and ZKN-013	07/23/07	CI
Eloxx Pharmaceuticals, Inc. Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome	14/23/14	CI
Eloxx Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	12/23/12	CI
Top Premarket Gainers	12/23/12	MT
Top Midday Gainers	11/23/11	MT
Oppenheimer Adjusts Eloxx Pharmaceuticals' Price Target to $55 From $50, Keeps Outperform Rating	11/23/11	MT
Transcript : Eloxx Pharmaceuticals, Inc. - Shareholder/Analyst Call	27/23/27
Eloxx Pharmaceuticals, Inc. Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients	15/23/15	CI
Top Premarket Decliners	16/23/16	MT
Eloxx Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	13/23/13	CI
Eloxx Pharmaceuticals Announces FDA Clearance to Begin Single Ascending Dose Study of ZKN-013	02/23/02	CI
Eloxx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	01/23/01	CI
Eloxx Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	31/23/31	CI

Chart Eloxx Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the science of ribosome modulation, leveraging both its TURBO- ZM chemistry technology platform and its library of aminoglycosides to develop oral small-molecule ribosome modulating agents (RMAs) and eukaryotic ribosome selective glycosides (ERSGs) for the treatment of rare and ultra-rare genetic diseases. Its lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. The Company is also advancing ZKN-013 as an oral agent for the treatment of recessive dystrophic (RDEB)/ junctional epidermolysis bullosa (JEB) and familial adenomatous polyposis (FAP) patients with nonsense mutations. The Company also has preclinical programs focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, as well as rare ocular genetic disorders.

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.85 USD

Average target price

30 USD

Spread / Average Target

+3,429.41%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ELOXX PHARMACEUTICALS, INC.	-31.13%	2.81M
VERTEX PHARMACEUTICALS INCORPORATED	+9.83%	118B
REGENERON PHARMACEUTICALS, INC.	+10.80%	106B
BIONTECH SE	-10.84%	23.4B
ARGENX SE	-1.69%	22.1B
GENMAB A/S	-10.23%	18.34B
WUXI APPTEC CO., LTD.	-41.92%	16.59B
BEIGENE, LTD.	-15.11%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+6.62%	14.03B
SAREPTA THERAPEUTICS, INC.	+17.53%	11.67B

Bio Therapeutic Drugs